Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline
Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline
复制标题
DOI：
10.1111/j.1365-2516.2009.02020.x
复制
发表时间：
2009-07-01
期刊：
影响因子：
3.9
通讯作者：
Mauser-Bunschoten, E. P.
中科院分区：
文献类型：
--
作者：
Schutgens, R. E. G.;Tuinenburg, A.;Mauser-Bunschoten, E. P.
Since the introduction of clotting factor concentrates, life expectancy of haemophilia patients is increasing and now approaches that of the general male population. Increasingly, haemophilia patients are confronted with age-related co-morbidity, including ischaemic cardiovascular disease. Treatment of stable angina pectoris and the acute coronary syndrome with antithrombotic therapy and percutaneous coronary intervention in haemophilia patients is feasible, but requires a tight co-operation between all specialists involved. As evidence-based guidelines are lacking, we developed a protocol on how we will treat haemophilia patients with ischaemic heart disease.
